TITLE

APTT in Heparinized Plasma: Influence of Reagent, Acute-Phase Reaction, and Interval Between Sampling and Testing

AUTHOR(S)
Strekerud, Finn G.; Abildgaard, Ulrich
PUB. DATE
October 1996
SOURCE
Clinical & Applied Thrombosis/Hemostasis;Fall1996, Vol. 2 Issue 4, p250
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Plasma samples from 10 healthy persons and 10 patients with acute-phase reaction were heparinized in vitro to obtain 0.00-0.70 U/ml. The activated partial thromboplastin time (aPTT) was then determined, using an optical method (Automated Coagulation Laboratory) and four reagents (actin, Cephotest, Platelin, and Thrombosil). The heparin sensitivity showed variation between individuals and was lower in acute-phase plasma than in normal plasma. There was also a marked difference in heparin sensitivity among the different reagents: actin was the least sensitive reagent, while Platelin was the most sensitive reagent in normal plasma and Thrombosil the most heparin-sensitive reagent in acute-phase plasma. Delay in testing prolonged the aPTT values in both acute-phase and normal heparinized plasma. With actin and Cephotest, a delay of 90 min at 22°C resulted in 30-50% prolongation of the aPTT. A delay of 150 min caused prolongation of 75-110% with actin. Cephotest, Platelin, and Thrombosil were less prolonged. Ex vivo samples from heparinized plasma showed similar degrees of prolongation. Storage at 4°C resulted in less prolongation. Assuming a therapeutic range of 0.35-0.70 U/ml of heparin. the therapeutic aPTT ratio ranges in heparinized. acute-phase plasma were 1.5-3.0 for actin and 2.5-4.5 for Cephotest, Platelin, and Thrombosil. These results underscore certain limitations in monitoring heparin therapy with the aPTT system. Unless the assay is performed within 30 min after sampling, unduly prolonged aPTT values will be recorded. This may lead to underdosing of the patient.
ACCESSION #
17104713

 

Related Articles

  • Usporedba reagensa Pathromtin SL, Dade Actin FS i STA Cephascreen za odreÄ‘ivanje aktiviranog parcijalnog tromboplastinskog vremena. Ðerek, Lovorka; Živković, Marcela; Haćperger, Dragica; Juriček, Jasna; Željko Romić // Biochemia Medica;Apr2008, Vol. 18 Issue 1, p81 

    Aim: Aim of the study was to investigate correlation of activated partial thromboplastin time (APTT) measured with three different reagents: Pathromtin SLand Dade Actin FS reagents on Berichrom Coagulation System analyzer, and by STA Cephascreen reagent on STA Compact analyzer. Material and...

  • Acute intralipid infusion reduces cardiac luminal lipoprotein lipase but recruits additional enzyme from cardiomyocytes. Qi, Dake; Kuo, Kuo-Hsing; Abrahani, Ashraf; An, Ding; Qi, Yadan; Heung, Jessica; Kewalramani, Girish; Pulinilkunnil, Thomas; Ghosh, Sanjoy; Innis, Sheila M.; Rodrigues, Brian // Cardiovascular Research;Oct2006, Vol. 72 Issue 1, p124 

    Abstract: Objective: Lipoprotein lipase (LPL) metabolizes the triglyceride (TG) core of lipoproteins. We evaluated whether circulating lipids can regulate LPL by influencing the transfer of enzyme from the myocyte to the endothelial lumen. Methods: Acute intralipid (IL, 10% and 20%) infusion was...

  • Differential Effects of Unfractionated Heparin and Low-Molecular-Weight Heparins on Tissue Thromboplastin Inhibition Test. Gerbutavicius, Rolandas; Iqbal, Omer; Messmore, Harry; Hoppensteadt, Debra A.; Demir, Muzaffer; Khan, Erum; Bacher, Peter; Fareed, Jawed // Clinical & Applied Thrombosis/Hemostasis;Oct2000, Vol. 6 Issue 4, p190 

    Circulating anticoagulants are endogenously produced substances that interfere with in vitro tests of coagulation like activated partial thromboplastin time (APTT). and cause prolongation of the clotting times. Evaluation of the abnormal APTT involving various factor assays and mixing studies...

  • The influence of acetaldehyde and glycosaminoglycans upon Factor Xa- and Factor X-deficient plasma. Brecher, Arthur S.; Hommema, Eric L. // Canadian Journal of Physiology & Pharmacology;Sep2002, Vol. 80 Issue 9, p879 

    The comparative effects of glycosaminoglycans and acetaldehyde (AcH) - glycosaminoglycan (GAG) mixtures upon Factor Xa- (FXa) and Factor X-deficient plasma (FXDP) have been studied by activated partial thromboplastin time (APTT) studies. Heparin at 0.025, 0.030, 0.04, and 0.05 U statistically...

  • Heparin-tissue Factor Pathway Inhibitor Complexes: Anticoagulant and Pharmacokinetic Properties. Tze-Chein Wun; Palmier, Mark O. // Clinical & Applied Thrombosis/Hemostasis;Jul1998, Vol. 4 Issue 3, p179 

    Exogenous addition of full-length tissue factor pathway inhibitor (FL-TFPI) to plasma caused a greater prolongation of prothromin time (PT) than activated partial thromboplastin time (APTT). In contrast, heparin elicited a greater prolongation of APTT than PT. These results suggest that FL-TFPI...

  • aPTT in Heparinized Patients: Influence of the Interval Between Sampling and Testing. Rachakonda, Vikrant; Rachakonda, Leelanand; Belliveau, Robert R. // Clinical & Applied Thrombosis/Hemostasis;Jul1998, Vol. 4 Issue 3, p213 

    Activated partial thromboplastin times(aPTTs) from, 29 whole blood samples were drawn from patients receiving unfractionated heparin through a constant intravenous drip. Three aPTTs were determined for each whole blood sample. The first aPTT was performed on a separate portion of the original...

  • Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II. Grouzi, Elisavet // Journal of Blood Medicine;2014, Vol. 5, p131 

    Heparin-induced thrombocytopenia (HIT) is a rare but potentially severe complication of heparin therapy that is strongly associated with venous and arterial thrombosis (HIT and thrombosis syndrome, HITTS), which requires urgent detection and treatment with a nonheparin anticoagulant. Argatroban,...

  • A Simple Tool to Educate Laboratory Staff About Anticoagulation. Mark Steciuk // Laboratory Medicine;Nov2009, Vol. 40 Issue 11, p687 

    Tests to monitor anticoagulation comprise a large percentage of the work of coagulation laboratories simply due to the large number of patients who receive anticoagulants such as heparin and warfarin. Despite the highly specialized and challenging nature of some coagulation tests, even the...

  • Laboratory Monitoring of Heparin: Challenges and Opportunities. Anne Winkler; Chelsea Sheppard; Corinne Fantz // Laboratory Medicine;Aug2007, Vol. 38 Issue 8, p499 

    Heparin, an anticoagulant used for the treatment and prophylaxis of thrombosis, is most commonly monitored using the activated partial thromboplastin time (APTT). Despite its widespread use, the APTT has limitations which stem from the coagulation factors it measures and the technical...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics